Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

Fossard, Gaëlle; Broussais, Florence; Coelho, Inês; Bailly, Sébastien; Nicolas‐Virelizier, Emmanuelle; Toussaint, Elise; Lancesseur, Charles; Bras, Fabien Le; Willems, Évelyne; Tchernonog, Emmanuelle; Chalopin, Thomas; Delarue, Richard; Gressin, Rémy; Chauchet, Adrien; Gyan, Emmanuel; Cartron, Guillaume; Bonnet, Christophe; Haı̈oun, Corinne; Damaj, Gandhi; Gaulard, Philippe; Fornecker, Luc; Ghesquières, Hervé; Tournilhac, Olivier; Silva, M. Gomes da; Bouabdallah, Réda; Salles, Gilles; Bachy, Emmanuel

doi:10.1093/annonc/mdx787

Cited by 115 publications

(105 citation statements)

References 25 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…However, these data cannot support that patients with PTCL-NOS, AITL or ALK-ALCL with CR or PR after induction do not show an improved outcome. The current data does not support the use of ASCT for up-front consolidation in all PTCL-NOS, AITL or ALK-ALCL patients with partial or complete response after induction [17]. A meta-analysis of PTCL Allogeneic Transplantation suggested that the 3-year OS of PTCL patients with allogeneic transplantation was 49.6%.…”

Section: Traditional Treatmentcontrasting

confidence: 62%

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Wang

Zhang

2019

Hematology

View full text Add to dashboard Cite

Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK-ALCL) is a definite entity in the WHO 2016 Classification that represents 2-3% of non-Hodgkin lymphoma (NHL) and 12% of T-cell NHL cases. ALK-ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL). Some studies indicate that ALK-ALCL and ALK+ ALCL possess different molecular and genetic characteristics. Besides, ALK-ALCL is worse than ALK+ ALCL in terms of treatment outcome, prognosis, and long-term survival. This review is aimed at summarizing information about ALK-ALCL, especially with respect to the treatment and prognosis.

show abstract

Section: Traditional Treatmentcontrasting

confidence: 62%

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Wang

Zhang

2019

Hematology

View full text Add to dashboard Cite

show abstract

“…Recent retrospective analyses shed doubt if consolidative HDT/ASCT is indicated in all patients achieving remission with conventional chemotherapy. 48…”

Section: Hdt and Asctmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas

Schmitz

Lenz

Stelljes

2018

Blood

View full text Add to dashboard Cite

Mature T- and natural killer (NK)-cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinically heterogeneous disorders with generally unfavorable outcome. Results of first-line chemotherapy are unsatisfactory for the most common T-cell lymphomas (peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphomas; anaplastic lymphoma tyrosine kinase-negative) as well as for many other entities. High-dose therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is widely recommended for consolidation after a complete or partial remission is achieved. However, about one-third of patients never reach transplantation because of early relapse or refractoriness. Targeted therapies have recently been developed; combinations with chemotherapy may improve outcomes, but long-term results from prospective studies are largely missing. In this situation, allogeneic HSCT remains a valuable treatment option inducing long-lived remissions in about 30% to 50% of patients with relapsed and refractory T-cell lymphoma able to proceed to transplantation. Results of allogeneic transplantation for consolidation in first remission are less defined and its indications remain controversial. With growing evidence that haploidentical HSCT also works in lymphoma, more patients can be brought to transplantation. Decreasing the morbidity and mortality of allogeneic transplantation is a continuous challenge. Integrating new drugs into transplant concepts and setting up prospective studies involving allogeneic transplantation remain unmet needs that warrant urgent study in a group of disorders in which classical chemotherapy and new drugs have generated results, which are far from optimal until today.

show abstract

“…9 On the other hand, said Dr. Advani, data from the LYSA study do not support the use of autologous stem cell transplant for upfront consolidation in patients with PTCL-NOS, AITL, or ALK-ALCL who have achieved a complete or partial response after induction. 10 "If patients are young and have achieved remission or even a partial response, most of us tend to transplant because outcomes with relapsed disease are very poor," Dr. Advani concluded. "None of the approved drugs are home runs.…”

Section: Patient Case Study 1: Peripheral T-cell Lymphomamentioning

confidence: 99%

Patient Case Studies and Panel Discussion: Lymphoma

2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

A heterogeneous group of diseases, lymphomas encompass a range of diagnoses that call for varied treatment approaches. Although some lymphomas require minimal intervention for cure or remission, others can be very difficult to treat and are associated with poor outcomes. At the NCCN 2019 Annual Congress: Hematologic Malignancies, a panel of experts used 3 case studies to develop an evidence-based approach for the treatment of patients with lymphomas. Moderated by Ranjana H. Advani, MD, the session focused on peripheral T-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.

show abstract

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

Abstract: The present data do not support the use of ASCT for up-front consolidation for all patients with PTCL-NOS, AITL, or ALK-ALCL with partial or complete response after induction.

Cited by 115 publications

References 25 publications

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas

Patient Case Studies and Panel Discussion: Lymphoma

Contact Info

Product

Resources

About